Alvotech proposed biosimilar to Stelara accepted by EMA
The companies anticipate that the EMA could also recommend marketing authorisation for AVT04
Read More
Tag: stelara
US expands scope of Janssen’s Stelara
The new approval cover paediatric patients with plaque psoriasis
Read More
Final NICE green light for Janssen’s Stelara in UC
The drug will be funded on the NHS to treat ulcerative colitis under certain conditions
Read More
NICE u-turn backs Stelara for UC
Stelara is the first biologic therapy for UC that targets interleukin (IL)-12 and IL-23 cytokines
Read More
SMC accepts four medicines for NHS use
Biogen’s Famprya, Sanofi’s Suliqua, Janssen’s Stelara and Shionogi Rizmoic will be funded on the NHS in Scotland
Read More
NICE rejects Janssen’s Stelara on cost efficiency grounds
The annual treatment costs are £14,482 in the induction year, and £9,304 per year for maintenance treatment.
Read More
Janssen files Stelara in Europe for ulcerative colitis
Janssen has submitted an application to the European Medicines Agency (EMA) seeking to expand the approval of Stelara to include the treatment of adults with moderately to severely active ulcerative colitis (UC).
Read More
Stelara induces remission in ulcerative colitis patients
Janssen has presented new data showing that a single dose of its biologic Stelara induced clinical remission and response in patients with moderate to severe ulcerative colitis.
Read More
Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial
Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.
Read More
US expands scope of J&J’s biologic Stelara in psoriasis
US regulators have approved an expansion of Johnson & Johnson’s Stelara to include younger patients with plaque psoriasis.
Read More
NICE backs Humira, Enbrel and Stelara for plaque psoriasis in children
AbbVie’s Humira, Pfizer’s Enbrel, and Janssen’s Stelara are being recommended as options for treating plaque psoriasis in children and young people on the NHS.
Read More
SMC bars access to Actelion’s Uptravi on NHS Scotland
Actelion says it is disappointed with a decision by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
